All In Biotech

Drug Trial Radar · NCT04785820

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

190

Actual

Start

Jun 25, 2021

Primary completion

Jan 30, 2025

Study completion Jan 30, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Mar 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, randomized, blinded, active-controlled, global, multicenter study designed to evaluate the safety and efficacy of lomvastomig and tobemstomig, compared with nivolumab, in patients with advanced or metastatic esophageal squamous-cell carcinoma (ESCC) refractory or intolerant to fluoropyrimidine- or taxane- and platinum-based regimen. Following approval of the protocol amendment version 3, recruitment into the lomvastomig arm has been stopped. The decision to stop recruitment for lomvastomig was based on strategic considerations and not based on emerging safety and/or efficacy data. The benefit/risk assessment for lomvastomig remains unchanged. The study was planned to enroll participants randomized in a 1:1:1 ratio to receive lomvastomig, tobemstomig, or nivolumab. With version 3 of the protocol, recruitment into the lomvastomig arm has stopped, and moving forward, participants will be randomized in a 1:1 ratio to receive either tobemstomig or nivolumab.

Conditions

  • Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventions

  • LomvastomigDrug

    2100 milligrams (mg) administered by intravenous (IV) infusion once every 2 weeks on Day 1 of each 14-day cycle.

  • TobemstomigDrug

    2100 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.

  • NivolumabDrug

    240 mg administered by IV infusion once every 2 weeks on Day 1 of each 14-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization to death (up to approximately 38.7 months)

Locations

52 sites in 18 countries. Site status is shown where the registry gives one.

  • Inst. Alexander Fleming

    Buenos Aires, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Masaryk?v onkologický ústav

    Brno, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Rigshospitalet

    København Ø, Denmark

  • Odense Universitetshospital, Onkologisk Afdeling R

    Odense C, Denmark

  • Hopital Claude Huriez

    Lille, France

  • Centre Leon Berard

    Lyon, France

  • Hopital Timone Adultes

    Marseille, France

  • Institut régional du Cancer Montpellier

    Montpellier, France

  • APHP - Hopital Saint Antoine

    Paris, France

  • ICO Rene Gauducheau

    Saint-Herblain, France

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, Hungary

  • Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS

    Meldola, Emilia-Romagna, Italy

  • Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della

    Udine, Friuli Venezia Giulia, Italy

  • IRCCS Istituto Oncologico Veneto (IOV)

    Padova, Veneto, Italy

  • International Cancer Institute (ICI)

    Eldoret, Kenya

  • The Aga Khan University-Kenya.

    Nairobi, Kenya

  • Centrum Onkologii w Bydgoszczy

    Bydgoszcz, Poland

  • Szpital Morski im. PCK

    Gdynia, Poland

  • Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II

    Krakow, Poland

  • NIO im Marii Sklodowskiej-Curie

    Warsaw, Poland

  • Bashkirian Republican Clinical Oncology Dispensary

    Ufa, Bashkortostan Republic, Russia

  • First Moscow State Medical University n.a. I.M. Sechenov

    Moscow, Moscow Oblast, Russia

  • MEDSI Clinical Hospital on Pyatnitsky Highway

    Moscow, Moscow Oblast, Russia

  • Group of companies "Medci"

    Moskva, Moscow Oblast, Russia

  • National Cancer Centre

    Singapore, Singapore

  • Curie Oncology

    Singapore, Singapore

  • Chonnam National University Hwasun Hospital

    Jeollanam-do, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hospital Clínic i Provincial

    Barcelona, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Complejo Hospitalario de Navarra

    Pamplona, Navarre, Spain

  • Changhua Christian Hospital

    Chang-hua, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • National Taiwan University Hospital

    Zhongzheng Dist., Taiwan

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.